Thrush and fever as markers of immune competence in the era of highly active antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 17, Issue 14, 2001, Pages 1311-1316

  Skolasky, R L ^a   Phair, J ^b   Detels, R ^c   Riddler, S ^d   Margolick, J ^a   Jacobson, L P ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CELL COUNT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE MARKER; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOCOMPETENCE; INFORMATION PROCESSING; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; T LYMPHOCYTE; THRUSH;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIGENS, DIFFERENTIATION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CANDIDIASIS, ORAL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; FEVER; HIV-1; HUMANS; IMMUNOCOMPETENCE; LYMPH NODES; NAD+ NUCLEOSIDASE;

EID: 0034754190     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220152596551     Document Type: Article

References (31)

1. Hit HIV-1 hard, but only when necessary
2. Immune restoration with antiretroviral therapies: Implications for clinical management
3. Immune reconstitution in HIV infection
4. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
5. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy
6. Positive effects of combined antiretroviral therapy on CD4+ T-cell homeostasis and function in advanced HIV disease
7. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease
8. Long-term immunological response in HIV-1 infected subjects receiving antiretroviral therapy
9. Immunologic response associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315
10. Thrush and fever as measures of immunocompetence in HIV-1-infected men
11. A simple clinical staging system that predicts progression to AIDS using CD4 count, oral thrush, and night sweats
12. Predictive value of viral load and other markers for progression to clinical AIDS after CD4+ T-cell count falls below 200/μl
13. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy
14. Comparison of clinical manifestations of HIV infection among women by risk group, CD4+ T-cell count, and HIV-1 plasma viral load. HER Study Group. HIV Epidemiology Research
15. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma among HIV-1 infected individuals
16. Rationale, organization, and selected characteristics of the participants
17. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA Panel
18. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome
19. Quality control in the flow cytometric measurement of T-lymphocyte subsets: The Multicenter AIDS Cohort Study experience
20. Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program
21. Longitudinal data analysis using generalized linear models
22. Infection with the human immunodeficiency virus: Clinical manifestations and their relationship to immune deficiency - A report from the Multicenter AIDS Cohort Study
23. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome
24. Tolerability and toxicity of protease inhibitor, containing regimens in HIV infected patients
25. Increase and plateau of CD4 T-cell counts in the 3 1/2 years after initiation of potent antiretroviral therapy
26. Factors influencing T-cell turnover in HIV-1-seropositive patients
27. HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: A viral-suppression-independent mechanism
28. Reversal of human immunodeficiency virus type1-associated hematosuppression by effective antiretroviral therapy
29. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men
30. Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center